Regulatory FDA points to liver injury with Amgen’s Tavneos PharmaphorumThe FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Eli Lilly outlays $7.8bn to acquire sleep drug biotech CentessaNext: Telomir seeks FDA approval for Telomir-1 to treat breast cancer Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026